These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23336356)

  • 21. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
    Bakst AE; Gaine SP; Rubin LJ
    Chest; 1999 Oct; 116(4):1127-9. PubMed ID: 10531185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled areosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation.
    Della Rocca G; Coccia C; Costa MG; Pompei L; Di Marco P; Vizza CD; Venuta F; Rendina EA; Pietropaoli P; Cortesini R
    Transplant Proc; 2001; 33(1-2):1634-6. PubMed ID: 11267451
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension.
    Raeisi-Giglou P; Wang XF; Dakkak W; Bair N; Dweik RA; Tonelli AR
    Chest; 2017 May; 151(5):1189-1192. PubMed ID: 28483121
    [No Abstract]   [Full Text] [Related]  

  • 24. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rebound effect after prostacyclin inhalation in pulmonary hypertension].
    Moro JA; Almenar L; Morales P; Osa A
    Med Clin (Barc); 2007 Jul; 129(7):279. PubMed ID: 17683713
    [No Abstract]   [Full Text] [Related]  

  • 26. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The successful management of severe protamine-induced pulmonary hypertension using inhaled prostacyclin.
    Jerath A; Srinivas C; Vegas A; Brister S
    Anesth Analg; 2010 Feb; 110(2):365-9. PubMed ID: 19933533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nebulized prostacyclin treatment for pulmonary hypertension in a 2-year-old girl].
    Puigarnau Vallhonrat R; Pons Odena M; Carballo Ruano E
    An Esp Pediatr; 2000 Oct; 53(4):372-6. PubMed ID: 11083992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
    Nakayama T; Ishikita T; Matsuura H; Saji T
    J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.
    Haché M; Denault A; Bélisle S; Robitaille D; Couture P; Sheridan P; Pellerin M; Babin D; Noël N; Guertin MC; Martineau R; Dupuis J
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):642-9. PubMed ID: 12658208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.
    Thomas IC; Glassner-Kolmin C; Gomberg-Maitland M
    Int J Cardiol; 2013 Oct; 168(4):4117-21. PubMed ID: 23890862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.
    Aguilar RV; Farber HW
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1846-50. PubMed ID: 11069824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
    Frost AE; Quiñones MA; Zoghbi WA; Noon GP
    J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
    Reddy MT; Patel H; Ventura HO
    Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
    [No Abstract]   [Full Text] [Related]  

  • 36. A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy.
    Ewert R; Halank M; Bruch L; Ghofrani HA
    Am J Respir Crit Care Med; 2012 Dec; 186(11):1196-8. PubMed ID: 23204382
    [No Abstract]   [Full Text] [Related]  

  • 37. Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
    Lawhorn S; Lawhorn CD; Davison C
    J Heart Lung Transplant; 1997 Apr; 16(4):472-3. PubMed ID: 9154961
    [No Abstract]   [Full Text] [Related]  

  • 38. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary hypertension trials: current end points are flawed, but what are the alternatives?
    Roberts K; Preston I; Hill NS
    Chest; 2006 Oct; 130(4):934-6. PubMed ID: 17035418
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls.
    Forrest IA; Small T; Corris PA
    Clin Sci (Lond); 1999 Jul; 97(1):99-102. PubMed ID: 10369800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.